Products & Reviews

Svar specializes in creating cell-based Reporter Gene Assays with iLite® technology for a range of applications. This technology offers a precise, sensitive system with luciferase readout, suitable for testing drug activity, immunogenicity, and Fc-functional assays including CDC, ADCC, and ADCP activity. Svar's development capabilities cover nearly any pharmaceutical target, ensuring rapid and accurate assays.

Svar specializes in creating cell-based Reporter Gene Assays with iLite® technology for a range of complement applications. This technology offers a precise, sensitive system with luciferase readout, suitable for assessing drug activity for different targets such as C5a, and through Complement-Dependent Cytotoxicity (CDC) activity.

The iLite® C5a Assay Ready Cells can be used for the quantification of C5a activity, and for determination of inhibitory activity against either C5a itself or against the C5a receptor in test samples, including human serum.

The AAV-TAb custom ELISA allows for the determination and quantification of total antibody binding to AAV vectors of different serotypes, including any potential custom capsid. This is achieved using your unique AAV preparation, eliminating the need for a surrogate AAV. Embrace the simplicity and flexibility of our two-step ELISA TAb.

With their proprietary technology, the iLite® technology Svar can develop Report Gene Assays – that area cleverly designed, sensitive and specific cell based reporter-gene system with luciferase readout. Svar can develop assays for virtually any pharmaceutical target that allow an easy, rapid and accurate test format for a wide range of applications, such as Immunogenicity and Potency assays.

The iLite® Functional Bioassay portfolio consists of cell lines provided in an “assay-ready” format for a rapid and convenient workflow. The assay-ready format also reduces assay variability, optimizing its use in screening, characterization, stability, and potency studies. iLite cell lines can be tailored to virtually any biopharmaceutical target.

The iLite® Fc Effector Reporter Gene Bioassays Portfolio offers a variety of reporter gene cell lines and target cells that can be used in MOA-reflective assays to measure the Fc effect of antibodies and other biologics that specifically bind and activate Fc receptors. Using a Luciferase reporter gene system offers a convenient and powerful way of measuring antibodies' in vitro efficacy in triggering ADCC and ADCP.

Svar offers assistance in gene therapy projects through robust platforms suited for all phases of drug development and experience from immunoassasy product development as well as their CRO services. Svar currently offer cell-based assays for Neutralizing antibody assessment and custom-made immunoassays for Total antibody assessment.

Complement biomarker assays target selected biomarkers of high relevance. These assays are important and well-suited for analyses in drug development and academic research. They stand out with very low cross-reactivity and high specificity as they bind neo-epitopes of cleaved products or complexes, where this is relevant.

In diagnosis of Rheumatoid Arthritis (RA), the measurement of anti-CCP is integral. People who test positive for Anti-CCP, are very likely to develop or have already developed RA, but not all who have RA, necessarily develop anti-CCP. Early detection of RA is crucial for reducing tissue damage.